Literature DB >> 16733096

Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.

Anne Kiang1, Zachary C Hartman, Ruth S Everett, Delila Serra, Haixiang Jiang, Michael M Frank, Andrea Amalfitano.   

Abstract

Excessive complement activation can result in extreme tissue damage and systemic inflammatory responses, similar to innate immune responses rapidly elicited after systemic adenovirus (Ad) injections. To determine if Ad interactions with the complement system impact upon Ad-induced innate immune responses, we injected Ad into complement-deficient, C3-knockout mice (C3-KO) or wild-type mice (WT) and quantitatively compared multiple anti-Ad innate immune responses in both strains of mice. In Ad-treated WT mice, we noted rapid increases in plasma KC levels (1 h post injection), followed by increases in IL-6, IFN-gamma, RANTES, IL-12(p40), IL-5, G-CSF, and GM-CSF and subsequently thrombocytopenia. Conversely, in Ad-treated C3-KO mice, many of these inflammatory responses were significantly blunted, including the avoidance of Ad-induced thrombocytopenia. Global liver transcriptome responses in Ad-treated WT mice were assessed by RT-PCR-validated gene array analysis and were found to be also significantly affected by the lack of complement activity in Ad-treated C3-KO mice. Finally, our results confirmed the ability of high dose Ads to transduce hepatocytes despite a lack of complement activity. In summary, Ad interactions with the mammalian complement system are significant and likely initiate and/or exacerbate many of the inflammatory responses noted after systemic Ad injections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16733096     DOI: 10.1016/j.ymthe.2006.03.024

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  42 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

2.  TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.

Authors:  D M Appledorn; S Patial; S Godbehere; N Parameswaran; A Amalfitano
Journal:  J Innate Immun       Date:  2009-03-04       Impact factor: 7.349

3.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

Review 4.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

5.  Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Authors:  Zachary C Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

6.  Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

Review 7.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Authors:  Zachary C Hartman; Daniel M Appledorn; Andrea Amalfitano
Journal:  Virus Res       Date:  2007-11-26       Impact factor: 3.303

Review 8.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

Review 9.  Progress and problems when considering gene therapy for GSD-II.

Authors:  A Kiang; A Amalfitano
Journal:  Acta Myol       Date:  2007-07

10.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.